Under fire for 5 deaths of patients taking Hemlibra, Roche spills details

30th March 2018 Uncategorised 0

Despite Roche’s insistence that the deaths of five patients taking its Hemlibra for hemophilia were not related to the drug, concerns arose on Wall Street that the news could stifle growth of the new product, which analysts had expected to rake in $4 billion or more in sales by 2022.

More: Under fire for 5 deaths of patients taking Hemlibra, Roche spills details
Source: fierce